comparemela.com

Page 3 - Vince Angotti News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx" or the "Company"), a specialty pharmaceutical company focused on the development and.

United statesVince angottiSecurities exchangePrnewswire acelrx pharmaceuticals incAcelrx pharmaceuticals incDrug administrationExchange commissionHc wainwright coNantahala capital managementPre funded warrantsPre funded warrantSecurities actAcelrx pharmaceuticalsBreakthrough device designation statusSecurities exchange act

Acelrx Pharmaceuticals Announces $10 Million Private Placement Of Securities Priced At-The-Market Under Nasdaq Rules

Acelrx Pharmaceuticals Announces $10 Million Private Placement Of Securities Priced At-The-Market Under Nasdaq Rules
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesVince angottiPrnewswire acelrx pharmaceuticals incAcelrx pharmaceuticals incDrug administrationHc wainwright coSecurities exchangeExchange commissionNasdaq stock marketPre funded warrantsPre funded warrantBreakthrough designationSecurities actBreakthrough device designation statusSecurities exchange act

AcelRx Pharma (ACRX) Announces 5 34M Share Private Placement at $1 36/sh

AcelRx Pharma (ACRX) Announces 5 34M Share Private Placement at $1 36/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaVince angottiHc wainwright coNasdaq stock marketExchange commissionDrug administrationAcelrx pharmaceuticals incSecurities exchangeAcelrx pharmaceuticalsPre funded warrantsPre funded warrantBreakthrough designationSecurities actBreakthrough device designation statusSecurities exchange act

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.

Vince angottiDepartment of defense doExchange commissionPrnewswire acelrx pharmaceuticals incAlora pharmaceuticalsAcelrx pharmaceuticals incCompany annual report on formEmergency use authorizationChief executive officerRecent corporateConference callDaylight timeUpcoming eventsBreakthrough device designation statusAcelrx pharmaceuticalsPrivate securities litigation reform act

AcelRx Pharmaceuticals completes divestment of DSUVIA to Alora Pharmaceuticals

California-based AcelRx Pharmaceuticals has completed the divestment of DSUVIA to Alora Pharmaceuticals.

Vince angottiDepartment of defenseOxford financeBreakthrough device designation status

vimarsana © 2020. All Rights Reserved.